Sylvain Mareschal, Ph.D.
Bioinformatics engineer
December 10, 2012 at 10:30
Jardin et al, ASH 2012
Related entries:
Oral communication
54th ASH Annual Meeting and Exposition (Atlanta, USA)
Session 622. Non-Hodgkin Lymphoma - Biology, excluding Therapy: Genetics of Diffuse Large B-cell Lymphoma (#415)

Integrated Analysis of High-Resolution Gene Expression and Copy Number Profiling Identified Biallelic Deletion of CDKN2A/2B Tumor Suppressor Locus As the Most Frequent and Unique Genomic Abnormality in Diffuse Large B-Cell Lymphoma (DLBCL) with Strong Prognostic Value in Both GCB and ABC Subtypes and Not Overcome by a Dose-Intensive Immunochemotherapy Regimen Plus Rituximab. Results of a Prospective GELA Clinical Trial Program

Jardin F, Mareschal S, Figeac M, Jaïs JP, Leroy K, Copie-Bergman C, Salles GA, Coiffier B, Delarue R, Peyrade F, Bosly A, Ketterer N, Haioun C, Tilly H, Molina TJ

Abstract on ASH Confex website